Contents
HEOR FELLOWSHIP PROGRAM 2027-2029
About Sanofi
Our determination to find answers for patients motivates us to develop life-changing medicines and vaccines. And to never settle.
Our cutting-edge science, technology and manufacturing capabilities have the potential to turn the impossible into the possible for millions of people around the world.
By chasing the miracles of science to improve people’s lives, we surprise ourselves with what we can achieve. And when we discover the extraordinary, we’re already planning where to go next.
About the University of Washington
The University of Washington is a world-class leader in health sciences education and has been consistently listed in US News and World Report as one of the top 10 institutions for its graduate programs. The University is particularly noted for its strong research programs and since 1974 has received more federal funds for research and training than any other public university in the United States. It fosters a highly collegial atmosphere between departments and academic units, creating a particularly attractive environment for such partnerships between the public and private sectors.
The Comparative Health Outcomes, Policy, and Economics (CHOICE) Institute is housed within the University of Washington School of Pharmacy, which boasts nearly 125 years of academic and research success. Faculty in the program (1) provide advanced research training for graduate students, postdoctoral fellows and clinicians (PharmDs, MDs), (2) conduct rigorous scientific research in economic evaluations and outcomes of pharmaceuticals and other health technologies, and (3) translate and disseminate the results of research into clinical practice and healthcare policy, with the goal of improving patient care.
The CHOICE Institute faculty participating in the fellowship have been chosen both for their dedication to teaching and their excellence in research. Each is trained either as a health economist or health services researcher and all have an extensive history of effective economic evaluations and pharmacoepidemiologic research.
Sean D. Sullivan, BScPharm, MSc, PhD
Professor of Pharmacy
The CHOICE Institute
University of Washington
sdsull@uw.edu
Ron Preblick, PharmD, MPH
Head, HEOR
US General Medicines Market Access
Sanofi
ronald.preblick@sanofi.com
Kendall Derber, PharmD
2026-2028 UW-Sanofi Fellow
PharmD, University of Utah
BA in Biochemistry and Molecular Biology, Bryn Mawr College
Kendall is a recent PharmD graduate from the University of Utah. She was first introduced to HEOR while working as a cell and gene therapy scientist, where she gained an appreciation for the role of advancing therapies. Her interest in HEOR further developed in pharmacy school as she conducted research on international drug pricing, treatment pathways, and policy impacts. At CHOICE, Kendall looks forward to further developing skills in real-world evidence generation and data analysis to improve patient outcomes and access to valuable therapies.
Kevin Li, PharmD, MS
2024-2026 UW-Sanofi Fellow
Thesis Title: Healthcare Resource Utilization and Costs of Commercially Insured US Patients with Atopic Dermatitis Switching from First-line to Second-line Systemic Targeted Therapies
Current Position: Associate Director, US HEVA Rare Disease Lead, Sanofi
Abstracts from fellowship:
- Li KH, Luong J, Devine B. Indirect Treatment Comparison of Biologic Treatments in Adolescents with Moderate to Severe Atopic Dermatitis: A Systematic Literature Review and Network Meta Analysis. ISPOR Europe 2024.
- Le QA, Kiener T, Johnson H, Khan R, Kong J, Li KH, Thompson G, Ozbay B, Greene M, Limburg P, Kisiel J, Ebner D. Systematic review of real-world adherence to blood-based laboratory tests for average-risk disease screening: potential implications for emerging colorectal cancer screening modalities. AACR Special Conference: Liquid Biopsy: From Discovery to Clinical Implementation 2024.
- Ng-Mak D, Thakker D, Ba Sarah, Li KH. Mortality Associated with Facioscapulohumeral Muscular Dystrophy: A Systematic Literature Review. Muscular Dystrophy Association 2025.
- Gray C, Diribe O, Oliveri D, Li KH, Phan B, Petruski-Ivleva N. Treatment patterns and time to non-response to advanced therapies among patients with moderate-to-severe atopic dermatitis in the United States: A claims analysis.
Manuscripts from fellowship:
- Li KH, Cousin EM, Gabriel N, Sullivan SD. Integrating Price Benchmarks and Comparative Clinical Effectiveness to Predict Initial Price Offers for Medicare Drug Price Negotiation (Initial Price Applicability Year 2027). Value Health. 2026 Jan;29(1):64-72. doi: 10.1016/j.jval.2025.09.3054. Epub 2025 Oct 1. PMID: 41043560.
- Kiener T, Li KH, Chiang E, Le QA. Impact of CDK4/6 inhibitors on health-related quality of life outcomes in patients with metastatic breast cancer: A systematic review and meta-analysis. J Manag Care Spec Pharm. 2025 Dec;31(12):1285-1303. doi: 10.18553/jmcp.2025.31.12.1285. PMID: 41296320; PMCID: PMC12658483.
- Li KH, Gray SL, Sullivan SD. Health care resource utilization and costs of commercially insured US patients with atopic dermatitis switching from first-line to second-line systemic targeted therapies. J Manag Care Spec Pharm. 2026 Jan;32(1):75-84. doi: 10.18553/jmcp.2026.32.1.75. PMID: 41439378; PMCID: PMC12728811.
- Li KH, Duffy EK, Luong J, Devine B. Biologic Treatments in Adolescents With Moderate-to-Severe Atopic Dermatitis: A Systematic Literature Review and Network Meta-analysis. Ann Pharmacother. 2026 Feb 4:10600280251415369. doi: 10.1177/10600280251415369. Epub ahead of print. PMID: 41635230.
- Li KH, Thakker D, Ba S, Hill AA, Ng-Mak D. Mortality associated with facioscapulohumeral muscular dystrophy: A systematic literature review. J Neurol Sci. 2026 Aug 15;487:125984. doi: 10.1016/j.jns.2026.125984. Epub 2026 May 7. PMID: 42134212.
The University of Washington/Sanofi HEOR Fellowship is a two-year program that provides formal training and hands-on experience in the HEOR field. The first year of the fellowship will consist of completing a Masters degree in Health Economics and Outcomes Research at the University of Washington, and the second year places the fellow in Sanofi’s Global Health Economics and Value Assessment (HEVA) department.
Fellowship Program Objectives
Upon completion of the experience, the HEOR/HEVA Fellow will be prepared to contribute within pharmaceutical organizations in numerous ways by drawing upon the following sample of skills developed:
- Design of outcomes research studies; use of descriptive and inferential statistics
- Publication within scientific/medical journals
- Resource development for use in patient treatment decisions
- Identification of unmet medical needs to drive research and communication planning
- Project management, including vendor supervision and common metrics reporting
- Working knowledge of relevant regulatory and compliance requirements
- In depth understanding of the US and Global healthcare environment, and the influence of payers on patient access to medicines
Fellowship Program First Year – University of Washington (Seattle, WA)
The objective of the first year is to provide the fellow with the research tools necessary for economic evaluation and policy assessment. The fellow will be given an overview of pharmaceutical economics and general health policy, and taught methods of economic assessment, health services research, epidemiology, clinical research design, and biostatistical analyses. The fellow will also complete an MS thesis project under the guidance of their University of Washington and Sanofi mentors.
Fellowship Program Second Year – Sanofi (Cambridge, MA)
The 2nd year of the fellowship places the fellow in Sanofi’s Global Health Economics and Value Assessment (HEVA) organization. HEVA has the mission of developing, translating, and communicating scientific evidence for use by health care providers, payers, and other customers to facilitate access and use of the best treatments for patients. A principal objective of HEVA is to demonstrate the value that Sanofi products bring to payers and other healthcare providers. HEVA accomplishes this goal by generating and publishing research studies, conducting collaborative projects with various stakeholders, and partnering with other functions of the broader Sanofi organization to develop solutions that address unmet medical needs and product value propositions.
The HEOR/HEVA Fellow will rotate through various US and Global HEVA functions, learning core skills related to conducting prospective and retrospective research studies, publishing data in scientific journals, developing customer support tools, and interacting with payers and stakeholders. This fellowship will provide a balanced exposure to best practices related to developing and communicating evidence, as well as a solid working knowledge of regulatory and legal guidelines inherent to these capabilities. The fellow is expected to grow professionally throughout their experience, engaging in projects of varying complexity and ultimately managing selected responsibilities with greater levels of independence.
Application Requirements
- You must hold U.S. citizenship or permanent residency status to apply. Unfortunately, we are unable to sponsor non-immigrant visas for this program nor do international students on OPT qualify.
- Degree in pharmacy or health-related discipline.
- Previous research experience (preference will be given to those with a high academic standing).
- Excellent oral and written communication skills, ethics, professionalism, leadership and an interest in the biopharmaceutical industry.
- Curriculum vitae, cover letter, three letters of recommendation.
Selection of fellows will be made by a committee composed of University of Washington faculty members and representatives from the respective company.
Key Dates:
- Eligibility: Degree in Pharmacy by July 1, 2027
- Application Opens: September 1, 2026
- Information Session: September 21, 2026
- Application Deadline: October 19, 2026
- Program Start Date: July 1, 2027
How to Apply
- Login to the Graduate School application portal.
- Select “Start Graduate Application”
- Complete all sections of the application along the left hand panel, starting with the Profile Information section.
- Under Program Selection, choose the following:
- Application type: Graduate
- Program: Pharmacy – Health Economics & Outcomes Research (MS)
- Review the Program Requirements and indicate the term and year you intend to enroll in the program
- Select Autumn 2027 (this is when the matriculation to the graduate program would begin).
- For the section, “Additional Materials”, download and complete the following Fellowship Selection Form.
- Upload the completed copy to your application.
- Continue with completing all other sections of the application, including Application Materials and Recommenders.
- Review your application and check for any missing required fields or errors. When ready, click Submit Application. Your application is not submitted until you have paid the application fee.
Download our detailed instruction guide.
Contact Information
Marina Gano, M.Ed.
Graduate Program & Operations Manager
The CHOICE Institute, Department of Pharmacy
uwsopchoice@uw.edu